NCT02146508

Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital

Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital (The EXPECT Trial) by Removal or Ablation of Esophageal Squamous Cell Dysplasia

• Status: Suspended
• Phase: N/A
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Tenwek Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Esophageal cancer is common in Kenya. The precursor of esophageal cancer is esophageal squamous dysplasia (ESD). In this study, persons known to have ESD will undergo endoscopic removal or ablation of ESD in order to prevent development of esophageal cancer.

Detailed description

Esophageal squamous dysplasia (ESD) is the precursor lesion of esophageal squamous cell cancer. ESD causes no symptoms but can be detected by screening. ESD may harbor various grades of dysplasia. Patients with moderate grade or high grade dysplasia (MGD or HGD) have up to a 40-fold increased risk of esophageal squamous cell cancer. In this study, persons known to have ESD with MGD or HGD on the basis of prior screening will be invited to undergo endoscopic treatment with either endoscopic mucosal resection (EMR) and/or radio frequency ablation (RFA) in order to remove or ablate regions of ESD. Participants will undergo a series of endoscopies to treat ESD and monitor success of treatment.

Conditions

• Esophageal Cancer
• Esophageal Squamous Dysplasia

Interventions

Type	Name	Description
PROCEDURE	Endoscopic Mucosal Resection (EMR)	Endoscopic removal of regions of ESD.
DEVICE	Radiofrequency ablation	Endoscopic radiofrequency ablation of regions of ESD

Timeline

• Start date: 2013-06-01
• Primary completion: 2024-07-01
• Completion: 2024-07-01
• First posted: 2014-05-23
• Last updated: 2023-12-11

Locations

1 site across 1 country: Kenya